These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37690873)

  • 1. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
    Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
    Guiñazú G; Dvorkin J; Mahmud S; Baral R; Pecenka C; Libster R; Clark A; Caballero MT
    Vaccine; 2024 Oct; 42(23):126234. PubMed ID: 39154512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
    Gebretekle GB; Yeung MW; Ximenes R; Cernat A; Simmons AE; Killikelly A; Siu W; Rafferty E; Brousseau N; Tunis M; Tuite AR
    Vaccine; 2024 Aug; 42(21):126164. PubMed ID: 39079810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
    Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
    BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan.
    Mizukami A; Preckler V; Verelst F; Matsuki T; Ho Y; Kurai D; Molnar D
    Expert Rev Vaccines; 2024; 23(1):986-996. PubMed ID: 39435476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
    Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
    BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
    Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
    BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.
    Baral R; Higgins D; Regan K; Pecenka C
    BMJ Open; 2021 Apr; 11(4):e046563. PubMed ID: 33895717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.
    Pecenka C; Sparrow E; Feikin DR; Srikantiah P; Darko DM; Karikari-Boateng E; Baral R; Vizzotti C; Rearte A; Jalang'o R; Fleming JA; Martinón-Torres F; Karron RA
    Lancet; 2024 Sep; 404(10458):1157-1170. PubMed ID: 39265588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
    Brault A; Pontais I; Enouf V; Debeuret C; Bloch E; Paireau J; Rameix-Welti MA; White M; Baudemont G; Lina B; Parent du Châtelet I; Casalegno JS; Vaux S; Cauchemez S
    Lancet Child Adolesc Health; 2024 Oct; 8(10):721-729. PubMed ID: 39208833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.
    Hutton DW; Prosser LA; Rose AM; Mercon K; Ortega-Sanchez IR; Leidner AJ; Havers FP; Prill MM; Whitaker M; Roper LE; Pike J; Britton A; Melgar M
    Vaccine; 2024 Oct; 42(24):126294. PubMed ID: 39241353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
    Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
    Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine During Pregnancy for Prevention of Respiratory Syncytial Virus Among Infants in Argentina.
    Rey-Ares L; Averin A; Zuccarino N; Vega CG; Kutrieb E; Quinn E; Atwood M; Weycker D; Law AW
    Infect Dis Ther; 2024 Nov; 13(11):2363-2376. PubMed ID: 39365506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
    Getaneh AM; Li X; Mao Z; Johannesen CK; Barbieri E; van Summeren J; Wang X; Tong S; Baraldi E; Phijffer E; Rizzo C; van Wijhe M; Heikkinen T; Bont L; Willem L; Jit M; Beutels P; Bilcke J;
    Vaccine; 2023 Feb; 41(9):1623-1631. PubMed ID: 36737318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.